Press releases

Intrasense announces its half-year results for 2024

25 September 2024

Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and developer of Myrian® et Liflow®, announces its consolidated IFRS half-year results for 2024.

See the press release

Guerbet and Intrasense announce the CE marking of DUOnco™ Liver, an artificial intelligence algorithm designed to detect focal liver lesions

23 September 2024

Guerbet (FR0000032526 GBT), worldwide leader in medical imaging, and Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and developer of Myrian® and Liflow®, announce the CE marking under MDR of the liver AI developed by Guerbet (trading name: DUOnco™ Liver).

See the press release

Intrasense attends the « Journées Francophones de Radiologie » 2024

9 September 2024

Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and Myrian® and Liflow® developer, announces its attendance in Journées Francophones de Radiologie (JFR) 2024, where will be presented for the first time the new solution Liflow® as well as the innovations of the new version of Myrian®.

See the press release

Alexandre Salvador appointed CEO of Intrasense to accelerate strategic repositioning on high value-added medical solutions integrating AI in radiology

27 August 2024

The Board of Directors of Intrasense (FR0011179886 - ALINS), metting on August, 28 2024 at 5:30 pm under the chairmanship of Mr. François NICOLAS, has decided to appoint Mr. Alexandre SALVADOR as Chief Executive Officer of Intrasense.

See the press release

Intrasense announces its 2024

25 July 2024

Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and developer of Myrian® and Liflow® (the "Company"), today announced its half-year revenue for 2024 IFRS consolidated at Group level.

See the press release

Intrasense presents its AI innovations at the SIRM congress in Italy

10 June 2024

Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and developer of Myrian® and Liflow®, announces its participation in SIRM, the congress organized by the Italian Society of Medical and Interventional Radiology, to be held from June 20 to 23 in Milan (Italy).

See the press release

Intrasense announces CE certification of Liflow® to the new European regulation (MDR)

29 April 2024

Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and developer of Myrian® and Liflow®, is proud to announce that the company has obtained CE certification under MDR (European Union Medical Device Regulation 2017/745), for the first version of its Liflow® solution.

See the press release

Intrasense announces the appointment of Jérôme Thiebaud as Chief Business Officer

24 April 2024

Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and developer of Myrian® and Liflow®, announces the appointment of Jérôme Thiebaud as the Group's Chief Business Officer.

See the press release

Liflow®: an innovative AI-enhanced solution to optimize oncology follow-up

16 April 2024

Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and developer of Myrian® and Liflow®, announces the regulatory submission of its Liflow® 1.0 solution (registered trademark of the Myra project), an oncology platform dedicated to the analysis of diagnostic imaging and cancer follow-up.

See the press release

Intrasense and Guerbet announce CE certification of Myrian 2.12, enhanced with Guerbet's prostate AI

8 April 2024

Intrasense (FR0011179886 - ALINS), a specialist in medical imaging software solutions and developer of Myrian®, and Guerbet (FR0000032526 GBT), world leader in medical imaging, are proud to announce that the Myrian® 2.12 platform has obtained CE certification under MDR, integrating prostate AI developed by Guerbet, the Veolity® LungCAD AI developed by MeVis Medical Solutions AG and the Icobrain™ AI developed by Icometrix. This market launch is a major step in the two companies' joint development plan and the realization of their growth ambitions.

See the press release
Subscribe